Join our community of smart investors

The Aim 100 2024: 20 to 11

The Aim 100 2024: 20 to 11
The Aim 100 2024: 20 to 11Published on November 7, 2024

20. Uniphar 

Dublin-based Uniphar (UPR) is a wholesaler and services provider to a broad range of pharmaceutical and medtech clients across the globe. They rely on it to source and deliver vital supplies in a closed supply chain. While Uniphar isn’t the only services-style healthcare business, the regulatory moat around its operations is wide, given public regulatory licences are typically required for its activities. 

September’s interim results followed a wide-ranging reorganisation of its structure, and there are signs that this is starting to have an impact. Gross profit growth in the first half hit 9.9 per cent, with Uniphar Pharma enjoying a particularly strong half as gross profits rose by more than a fifth. The supply chain and retail arm, meanwhile, has now finished the process of integrating the McCauley Pharmacy Group into its structure. 

This is subscriber only content
Start your trial to keep reading
PRINT AND DIGITAL

Get 12 weeks for £12
  • Essential access to the website and app
  • Magazine delivered every week
  • Investment ideas, tools and analysis
Already a subscriber? Sign in